Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4102967 | 0.98 | CYP2C19 (0.35) | CYP2C19TSHRCYP1A2LMNAUSP2 | |
| Bromide SCHEMBL346190 | 0.98 | CYP2C19 (0.35) | CYP2C19TSHRCYP1A2LMNAUSP2 | |
| SCHEMBL3019549 | 0.82 | — | — | |
| SCHEMBL25447009 | 0.79 | KDM4E (0.36) | CYP1A2ALDH1A1KDM4EKMT2ASMYD3 | |
| SCHEMBL8314863 | 0.79 | LMNA (0.35) | TSHRLMNAKDM4EKMT2ASMYD3 | |
| SCHEMBL16621056 | 0.78 | CYP1A2 (0.45) | CYP2C19TSHRCYP1A2LMNAUSP2 | |
| SCHEMBL322137 | 0.77 | — | — | |
| SCHEMBL2941358 | 0.77 | CYP2C19 (0.52) | CYP2C19TSHRCYP1A2LMNAUSP2 | |
| SCHEMBL304486 | 0.75 | CYP2C19 (0.56) | CYP2C19TSHRCYP1A2LMNAUSP2 | |
| SCHEMBL1555451 | 0.75 | CYP2C19 (0.56) | CYP2C19TSHRCYP1A2LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026088120-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260116880-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250230154-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-07-17 | — | — | US | disclosed |
| EP-4385991-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| CN-117881678-A | Compound with SHP2 protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2023018155-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018155-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-02-16 | — | — | WO | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| CN-114901277-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2010055267-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-05-20 | — | — | WO | disclosed |
| CN-101565420-A | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2009-10-28 | — | — | CN | disclosed |
| US-20080153801-A1 | Benzoxazepine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-20080153801-A1 | Benzoxazepine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-20070117787-A1 | Benzoxazepine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2007-05-24 | — | — | US | disclosed |
| US-20070117787-A1 | Benzoxazepine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2007-05-24 | — | — | US | disclosed |
| US-6710060-B2 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-12 | — | — | US | disclosed |
| EP-1182192-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-5922717-A | ANTICOAGULANTS | DR. KARL THOMAE GMBH (DE) | 1999-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117787-A1 | Benzoxazepine compounds, their production and use | NR1H2, APOB, CETP | CYP2C19 116/4885TSHR 675/4885CYP1A2 253/4885 |
| US-20250230154-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | PTPN1, PTPN5, PTPN2 | CYP2C19 4555/4885TSHR 3589/4885CYP1A2 4399/4885 |
| US-20260116880-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP2C19 4099/4885TSHR 1005/4885CYP1A2 3050/4885 |
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | SCN5A, RYR2, SCN1B | CYP2C19 640/4885TSHR 1387/4885CYP1A2 463/4885 |
| US-20080153801-A1 | Benzoxazepine compounds, their production and use | CETP, PCSK9, LPL | CYP2C19 57/4885TSHR 611/4885CYP1A2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.